9.82
price down icon2.58%   -0.26
pre-market  プレマーケット:  10.40   0.58   +5.91%
loading
前日終値:
$10.08
開ける:
$10.04
24時間の取引高:
209.04K
Relative Volume:
0.99
時価総額:
$174.17M
収益:
$1.54M
当期純損益:
$-78.54M
株価収益率:
-1.6427
EPS:
-5.978
ネットキャッシュフロー:
$-64.50M
1週間 パフォーマンス:
-4.61%
1か月 パフォーマンス:
+12.74%
6か月 パフォーマンス:
-42.64%
1年 パフォーマンス:
+30.93%
1日の値動き範囲:
Value
$9.6968
$10.29
1週間の範囲:
Value
$9.6968
$10.81
52週間の値動き範囲:
Value
$6.10
$20.56

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile

Name
名前
Corbus Pharmaceuticals Holdings Inc
Name
セクター
Healthcare (1107)
Name
電話
617-963-0103
Name
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Name
職員
36
Name
Twitter
@corbuspharma
Name
次回の収益日
2026-05-05
Name
最新のSEC提出書
Name
CRBP's Discussions on Twitter

Compare CRBP vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CRBP icon
CRBP
Corbus Pharmaceuticals Holdings Inc
9.82 174.17M 1.54M -78.54M -64.50M -5.978
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
430.14 109.41B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
731.77 76.72B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
775.03 48.20B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
302.11 40.31B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
298.16 33.13B 5.36B 287.73M 924.18M 2.5229

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-30 再開されました B. Riley Securities Buy
2025-02-28 開始されました William Blair Outperform
2024-12-02 開始されました Piper Sandler Overweight
2024-07-30 開始されました Wedbush Outperform
2024-07-22 再開されました H.C. Wainwright Buy
2024-06-26 開始されました B. Riley Securities Buy
2024-06-03 繰り返されました Oppenheimer Outperform
2024-05-13 開始されました RBC Capital Mkts Outperform
2024-03-06 アップグレード Jefferies Hold → Buy
2020-09-08 ダウングレード BTIG Research Buy → Neutral
2020-09-08 ダウングレード Jefferies Buy → Hold
2020-09-08 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-09-08 ダウングレード ROTH Capital Buy → Neutral
2020-07-07 開始されました ROTH Capital Buy
2020-06-17 開始されました BTIG Research Buy
2020-03-26 開始されました Nomura Buy
2019-04-05 開始されました Jefferies Buy
2019-03-20 開始されました Oppenheimer Outperform
2019-01-11 繰り返されました Cantor Fitzgerald Overweight
2018-12-26 開始されました H.C. Wainwright Buy
2018-12-07 開始されました RBC Capital Mkts Outperform
2018-10-24 開始されました B. Riley FBR Buy
2018-01-19 開始されました Raymond James Outperform
2017-12-14 繰り返されました Cantor Fitzgerald Overweight
2017-11-08 繰り返されました Noble Financial Buy
2017-09-29 再開されました Noble Financial Buy
2017-03-30 繰り返されました Cantor Fitzgerald Overweight
2016-11-15 繰り返されました JMP Securities Mkt Outperform
2016-11-11 繰り返されました Noble Financial Buy
すべてを表示

Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース

pulisher
Apr 28, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 28, 2026
pulisher
Apr 27, 2026

Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

Corbus offers upside despite post-FDA update, analyst highlights competitive edge - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share - MSN

Apr 27, 2026
pulisher
Apr 25, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat

Apr 25, 2026
pulisher
Apr 25, 2026

Discipline and Rules-Based Execution in CRBP Response - Stock Traders Daily

Apr 25, 2026
pulisher
Apr 25, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat

Apr 25, 2026
pulisher
Apr 24, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch

Apr 24, 2026
pulisher
Apr 24, 2026

CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill

Apr 24, 2026
pulisher
Apr 23, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Apr 23, 2026
pulisher
Apr 22, 2026

Corbus Pharmaceuticals (CRBP) Q4 2025 earnings summary - Quartr

Apr 22, 2026
pulisher
Apr 22, 2026

Corbus Pharmaceuticals (CRBP) Corporate presentation Summary - Quartr

Apr 22, 2026
pulisher
Apr 22, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 22, 2026
pulisher
Apr 22, 2026

Corbus Pharmaceuticals (CRBP) Registration Filing Summary - Quartr

Apr 22, 2026
pulisher
Apr 22, 2026

Corbus Pharmaceuticals (CRBP) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr

Apr 22, 2026
pulisher
Apr 22, 2026

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 - The Manila Times

Apr 22, 2026
pulisher
Apr 18, 2026

Corbus Pharmaceuticals Aligns with FDA on Cancer Drug Strategy - HarianBasis.co

Apr 18, 2026
pulisher
Apr 17, 2026

Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value - Insider Monkey

Apr 17, 2026
pulisher
Apr 16, 2026

Corbus Pharmaceuticals updates executive employment agreements for CEO and CFO - Investing.com UK

Apr 16, 2026
pulisher
Apr 16, 2026

Corbus Pharmaceuticals updates executive employment agreements for CEO and CFO By Investing.com - Investing.com South Africa

Apr 16, 2026
pulisher
Apr 16, 2026

Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections - TipRanks

Apr 16, 2026
pulisher
Apr 16, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) resets CEO and CFO pay, severance and CIC terms - Stock Titan

Apr 16, 2026
pulisher
Apr 16, 2026

Corbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists - BioWorld News

Apr 16, 2026
pulisher
Apr 15, 2026

5 Best Biotech Stocks Under $10 to Buy - Insider Monkey

Apr 15, 2026
pulisher
Apr 14, 2026

Corbus Pharmaceuticals (CRBP) Advances in Obesity Treatment Tria - GuruFocus

Apr 14, 2026
pulisher
Apr 14, 2026

Corbus completes enrollment in obesity drug trial By Investing.com - Investing.com Australia

Apr 14, 2026
pulisher
Apr 14, 2026

Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone - TipRanks

Apr 14, 2026
pulisher
Apr 14, 2026

Corbus completes enrollment in obesity drug trial - Investing.com

Apr 14, 2026
pulisher
Apr 14, 2026

Corbus Pharmaceuticals Holdings initiates last patient first visit in CANYON-1 obesity trial with 240 participants - Traders Union

Apr 14, 2026
pulisher
Apr 14, 2026

Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity - The Manila Times

Apr 14, 2026
pulisher
Apr 14, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) reaches key Phase 1b obesity trial milestone for CRB-913 - Stock Titan

Apr 14, 2026
pulisher
Apr 14, 2026

Corbus hits 240-patient milestone for oral obesity drug study - Stock Titan

Apr 14, 2026
pulisher
Apr 14, 2026

Behavioral Patterns of CRBP and Institutional Flows - Stock Traders Daily

Apr 14, 2026
pulisher
Apr 09, 2026

Published on: 2026-04-09 22:47:10 - baoquankhu1.vn

Apr 09, 2026
pulisher
Apr 08, 2026

Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch

Apr 08, 2026
pulisher
Apr 08, 2026

Corbus Pharmaceuticals Holdings, Inc. secures ASCO 2026 slot for new CRB-701 clinical findings - Traders Union

Apr 08, 2026
pulisher
Apr 08, 2026

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer - Sahm

Apr 08, 2026
pulisher
Apr 08, 2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm

Apr 08, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.77
price down icon 0.29%
$49.54
price down icon 0.22%
$102.06
price up icon 0.00%
$134.94
price down icon 0.76%
$144.83
price up icon 9.99%
ONC ONC
$298.16
price down icon 0.25%
大文字化:     |  ボリューム (24 時間):